智通财经APP讯，国富创新(00290)发布公告，于2024年11月4日至2025年1月15日(包括首尾两日)期间，卖方利威发展有限公司(公司的全资附属公司)于公开市场上透过一系列交易出售合共1886万股目标股份(今海医疗科技股份有限公司)(占目标公司于本公告日期的全部已发行股本约0.36%)，总代价约为2698万港元(不包括交易成本)，相当于平均价格约为每股目标股份1.43港元。
于2025年2月21日(交易时段后)，卖方与买方王强订立股份转让协议，卖方有条件同意出售而买方有条件同意收购4294万股目标股份(占目标公司于本公告日期的全部已发行股本约0.83%)，代价约为6012万港元，相当于售价约为每股目标股份1.40港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.